OBJECTIVE: To systematically evaluate the efficacy and safety of Mecobalamin tablets combined with Mudan granules in the treatment of diabetic peripheral neuropathy. METHODS: Embase

PubMed

the Cochrane Library

Wanfang Data

CNKI and CBM databases were retrieved to collect the randomized controlled trial（RCT） of Mecobalamin tablets combined with Mudan granules in the treatment of diabetic peripheral neuropathy（the study group was treated with Mecobalamine tablets combined with Mudan granules

while the control group received Mecobalamine tablets alone）

the retrieval time was from the establishment of the database to Mar. 2022. The Chinese database was limited to the statistical source journals of Chinese scientific and technical papers

and the English database did not make journal restrictions. After literature selection

data extraction and bias risk evaluation of included literature

RevMan 5.4 software was used for Meta-analysis. RESULTS: A total of 13 studies were enrolled

including 1 438 patients

with 745 cases in the study group and 693 cases in the control group. In terms of efficacy

the total effective rate（OR=3.31

95%CI=2.41-4.55

P<0.000 01）

significant effective rate（OR=2.23

95%CI=1.72-2.90

P<0.000 01）

motor conduction velocity（MCV） of median nerve（MD=2.91

95%CI=2.22-3.59

P<0.000 01）

MCV of common peroneal nerve（MD=4.94

95%CI=2.84-7.03

P<0.000 01）

MCV of anterior tibial nerve（MD=2.87

95%CI=2.22-3.52

P<0.000 01）

sensory conduction velocity（SCV） of median nerve（MD=3.95

95%CI=3.42-4.48

P<0.000 01）

SCV of common peroneal nerve（MD=5.11

95%CI=1.84-8.38

P=0.002） and SCV of anterior tibial nerve（MD=4.81

95%CI=3.89-5.73

P<0.000 01） in the study group were significantly better than those in the control group

the differences were statistically significant. In terms of safety

the incidence of adverse drug reactions in the study group was significantly lower than that in the control group

with statistically significant difference（OR=0.34

95%CI=0.14-0.83

P=0.02）. CONCLUSIONS: The available evidence suggests that Mecobalamin tablets combined with Mudan granules are safe and effective in the treatment of diabetic peripheral neuropathy

with significant advantages over Mecobalamin tablets alone. Due to the limitations of the number and quality of selected studies

the above findings need to be validated by more high-quality RCT in the future.